IP Library › Granted Patent US 12,416,049
Granted Patent B2
US 12,416,049 · App. 16/874,215 · Granted Sep 16, 2025

Methylation pattern analysis of haplotypes in tissues in a DNA mixture

Inventors: Yuk-Ming Dennis Lo (Kowloon, CN); Kwan Chee Chan (Jordan, CN); Rossa Wai Kwun Chiu (Shatin, CN); Peiyong Jiang (Shatin, CN); Kun Sun (Shatin, CN)
Assignee: The Chinese University of Hong Kong
C12Q1/6886C12Q1/6883G16B30/00C12Q2600/154C12Q2600/156C12Q2600/172
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,416,049
App. No.
16/874,215
Granted
Sep 16, 2025
Kind
B2
Abstract

Systems, apparatuses, and method are provided for determining the contributions of different tissues to a biological sample that includes a mixture of cell-free DNA molecules from various tissues types, e.g., as occurs in plasma or serum and other body fluids. Embodiments can analyze the methylation patterns of the DNA mixture (e.g., methylation levels at particular loci) for a particular haplotype and determine fractional contributions of various tissue types to the DNA mixture, e.g., of fetal tissue types or tissue types of specific organs that might have a tumor. Such fractional contributions determined for a haplotype can be used in a variety of ways.

Claims (85)

1. A method of analyzing a biological sample of an organism, the biological sample including a mixture of cell-free DNA molecules from a plurality of tissues types, including a first tissue type, the method comprising:

analyzing, by a computer system, a plurality of cell-free DNA molecules from the biological sample, the plurality of cell-free DNA molecules being at least 1,000 cell-free DNA molecules, wherein analyzing a cell-free DNA molecule includes:

identifying a location of the cell-free DNA molecule in a reference genome corresponding to the organism; and

determining a respective allele of the cell-free DNA molecule;

identifying one or more loci, each having a corresponding first allele on a first haplotype of a first chromosomal region, wherein the first haplotype is:

not present in healthy cells of the organism, or

present in the healthy cells of the organism and not present in abnormal cells that may be in the mixture;

identifying a first set of the plurality of cell-free DNA molecules that each:

is located at any one locus of the one or more loci,

includes the corresponding first allele of the one locus, and

includes at least one of N genomic sites, N being an integer greater than or equal to 2;

measuring N first mixture methylation levels at the N genomic sites using the first set of the plurality of cell-free DNA molecules;

determining, by the computer system, a first fractional contribution of the first tissue type in the first set of the plurality of cell-free DNA molecules from the mixture using the N first mixture methylation levels;

determining a first separation value between the first fractional contribution and a reference fractional contribution; and

comparing the first separation value to a threshold value to determine a classification of whether the first tissue type has a disease state.

2. The method of claim 1 , wherein the first haplotype is on a first chromosome, and wherein the first tissue type has the first haplotype on both copies of the first chromosome.

3. The method of claim 1 , wherein the first haplotype is not present in the healthy cells of the organism, and wherein the first haplotype is associated with the disease state.

4. The method of claim 3 , wherein the first tissue type is determined to have the disease state when the first separation value is greater than the threshold value.

5. The method of claim 3 , further comprising:

identifying a second set of the plurality of cell-free DNA molecules that each:

is located at any one of the one or more loci;

includes a corresponding second allele on a second haplotype of the first chromosomal region, the second haplotype not being present in the healthy cells of the organism, and the second haplotype associated with the disease state; and

includes at least one of the N genomic sites;

measuring N second mixture methylation levels at the N genomic sites using the second set of the plurality of cell-free DNA molecules;

determining, by the computer system, a second fractional contribution of the first tissue type in the second set of the plurality of cell-free DNA molecules from the mixture using the N second mixture methylation levels;

determining a second separation value between the second fractional contribution and the reference fractional contribution; and

comparing the second separation value to the threshold value as part of determining the classification of whether the first tissue type has the disease state.

6. The method of claim 3 , wherein the disease state is cancer.

7. The method of claim 6 , wherein a particular cancer has the first haplotype in a cancer genome of the particular cancer.

8. The method of claim 7 , wherein the particular cancer is selected from the group consisting of liver cancer, lung cancer, pancreas cancer, atrium cancer, colon cancer, sigmoid colon cancer, transverse colon cancer, ascending colon cancer, descending colon cancer, adrenal gland cancer, esophagus cancer, small intestines cancer, and CD4 T cell cancer.

9. The method of claim 6 , wherein the classification of whether the first tissue type has cancer comprises classification of a presence or an absence of the cancer, classification of a stage of cancer, classification of a size of a tumor, and/or classification of metastasis.

10. The method of claim 3 , further comprising performing, by the computer system:

determining a plurality of corresponding fractional contributions of other tissue types in the first set of the plurality of cell-free DNA molecules from the mixture using the N first mixture methylation levels;

determining corresponding separation values between the plurality of corresponding fractional contributions and corresponding reference fractional contributions; and

comparing the corresponding separation values to the threshold value to determine classifications of whether each of the other tissue types has the disease state.

11. The method of claim 3 , wherein the corresponding first allele at each of the one or more loci is a cancer-specific mutation.

12. The method of claim 1 , further comprising:

determining the corresponding first allele at each of the one or more loci on the first haplotype by:

analyzing DNA molecules of a tissue sample having the first haplotype to determine the first haplotype.

13. The method of claim 1 , wherein the disease state is a rejection of a transplant of the first tissue type in the organism.

14. The method of claim 13 , wherein the reference fractional contribution is determined from one or more measurements of biological samples of organisms with the first tissue type being healthy.

15. The method of claim 13 , wherein the reference fractional contribution is determined from one or more measurements of biological samples of organisms whose transplanted first tissue is not being rejected.

16. The method of claim 1 , wherein the reference fractional contribution is zero.

17. The method of claim 1 , wherein the N first mixture methylation levels form a methylation vector b, and wherein determining the first fractional contribution of the first tissue type includes:

for each of M tissue types:

obtaining N tissue-specific methylation levels at the N genomic sites, N being greater than or equal to M, wherein the N tissue-specific methylation levels form a matrix A of dimensions N by M, the M tissue types including the first tissue type, M being an integer greater than one;

solving for a composition vector x that provides the methylation vector b for the matrix A; and

for each component of one or more components of the composition vector x:

using the component to determine a corresponding fractional contribution of a corresponding tissue type of the M tissue types in the first set of the plurality of cell-free DNA molecules from the mixture.

18. The method of claim 1 , wherein the first haplotype is present in the healthy cells of the organism and not present in the abnormal cells that may be in the mixture.

19. The method of claim 18 , wherein the abnormal cells are from a tumor.

20. The method of claim 18 , wherein the abnormal cells are from donor tissue.

21. The method of claim 1 , wherein the first tissue type is determined to have the disease state when the first separation value is less than the threshold value.

22. A computer product comprising a non-transitory computer readable medium storing a plurality of instructions for analyzing a biological sample of an organism, the biological sample including a mixture of cell-free DNA molecules from a plurality of tissues types, including a first tissue type, wherein the plurality of instructions, when executed, cause one or more processors of a computer system to perform:

analyzing a plurality of cell-free DNA molecules from the biological sample, the plurality of cell-free DNA molecules being at least 1,000 cell-free DNA molecules, wherein analyzing a cell-free DNA molecule includes:

identifying a location of the cell-free DNA molecule in a reference genome corresponding to the organism; and

determining a respective allele of the cell-free DNA molecule;

identifying one or more loci, each having a corresponding first allele on a first haplotype of a first chromosomal region, wherein the first haplotype is:

not present in healthy cells of the organism, or

present in the healthy cells of the organism and not present in abnormal cells that may be in the mixture;

identifying a first set of the plurality of cell-free DNA molecules that each:

is located at any one locus of the one or more loci,

includes the corresponding first allele of the one locus, and

includes at least one of N genomic sites, N being an integer greater than or equal to 2;

measuring N first mixture methylation levels at the N genomic sites using the first set of the plurality of cell-free DNA molecules;

determining a first fractional contribution of the first tissue type in the first set of the plurality of cell-free DNA molecules from the mixture using the N first mixture methylation levels;

determining a first separation value between the first fractional contribution and a reference fractional contribution; and

comparing the first separation value to a threshold value to determine a classification of whether the first tissue type has a disease state.

23. A system for analyzing a biological sample of an organism, the biological sample including a mixture of cell-free DNA molecules from a plurality of tissues types, including a first tissue type, the system comprising:

an apparatus configured to perform an assay on a plurality of cell-free DNA molecules from the biological sample to provide measurement data, the plurality of cell-free DNA molecules being at least 1,000 cell-free DNA molecules;

a computer system configured to receive the measurement data and to perform:

analyzing the plurality of cell-free DNA molecules from the biological sample, wherein analyzing a cell-free DNA molecule includes:

identifying a location of the cell-free DNA molecule in a reference genome corresponding to the organism; and

determining a respective allele of the cell-free DNA molecule;

identifying one or more loci, each having a corresponding first allele on a first haplotype of a first chromosomal region, wherein the first haplotype is:

not present in healthy cells of the organism, or

present in the healthy cells of the organism and not present in abnormal cells that may be in the mixture;

identifying a first set of the plurality of cell-free DNA molecules that each:

is located at any one locus of the one or more loci,

includes the corresponding first allele of the one locus, and

includes at least one of N genomic sites, N being an integer greater than or equal to 2;

measuring N first mixture methylation levels at the N genomic sites using the first set of the plurality of cell-free DNA molecules;

determining a first fractional contribution of the first tissue type in the first set of the plurality of cell-free DNA molecules from the mixture using the N first mixture methylation levels;

determining a first separation value between the first fractional contribution and a reference fractional contribution; and

comparing the first separation value to a threshold value to determine a classification of whether the first tissue type has a disease state.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2020
From: LO, YUK-MING DENNIS; CHAN, KWAN CHEE; CHIU, ROSSA WAI KWUN; JIANG, PEIYONG; SUN, KUN
To: THE CHINESE UNIVERSITY OF HONG KONG
Reel/Frame 052667/0256 →
Continuity (3)
Division 15214998 · Jul 20, 2016
Provisional Application 62194702 · Jul 20, 2015
Related Publication 20200270707A1 · Aug 27, 2020
References Cited (31)
US 8467976B2 · Lo et al. · 2013 [cited by applicant]
US 10689706B2 · Lo et al. · 2020 [cited by applicant]
US 20140080715A1 · Lo et al. · 2014 [cited by applicant]
US 20140315200A1 · Lo et al. · 2014 [cited by applicant]
US 20150004601A1 · Struble et al. · 2015 [cited by applicant]
US 20160017419A1 · Chiu et al. · 2016 [cited by applicant]
US 20160340740A1 · Zhang · 2016 [cited by applicant]
US 20170121767A1 · Dor et al. · 2017 [cited by applicant]
CN 102770558A · 2012 [cited by applicant]
CN 103459614A · 2013 [cited by applicant]
CN 103492589A · 2014 [cited by applicant]
CN 104781422A · 2015 [cited by applicant]
TW 201418474A · 2014 [cited by applicant]
WO 2011018600A1 · 2011 [cited by applicant]
WO 2011057094A1 · 2011 [cited by applicant]
WO 2014043763A1 · 2014 [cited by applicant]
Australian Application No. 2016295712, First Examination Report mailed on Sep. 10, 2021, 4 pages. [cited by applicant]
Australian Application No. 2016295712, Notice of Acceptance mailed on May 24, 2022, 3 pages. [cited by applicant]
Chim et al., Detection of the Placental Epigenetic Signature of the Maspin Gene in Maternal Plasma, PNAS, vol. 102, No. 41, Oct. 11, 2005, pp. 14753-14758. [cited by applicant]
European Application No. 16827235.9, Extended European Search Report mailed on Jun. 27, 2018, 12 pages. [cited by applicant]
European Application No. 16827235.9, Office Action mailed on Apr. 8, 2019, 7 pages. [cited by applicant]
European Application No. 20183986.7, Extended European Search Report mailed on Sep. 28, 2020, 8 pages. [cited by applicant]
European Application No. 22162789.6, Extended European Search Report mailed on Aug. 31, 2022, 12 pages. [cited by applicant]
Hill et al., Uses of Cell Free Fetal DNA in Maternal Circulation, Best Practice & Research: Clinical Obstetrics & Gynaecology, vol. 26, No. 5, Oct. 2012, pp. 639-654. [cited by applicant]
Nygren et al., Quantification of Fetal DNA by Use of Methylation-Based DNA Discrimination, Clinical Chemistry, vol. 56, No. 10, Available Online at: http://www.clinchem.org/content/supp1/2010/07/28/clinchem.2010.146290.… [cited by applicant]
Ou et al., Epigenome-Wide DNA Methylation Assay Reveals Placental Epigenetic Markers for Noninvasive Fetal Single-Nucleotide Polymorphism Genotyping in Maternal Plasma, Transfusion, vol. 54, No. 10, Oct. 2014, pp. 2523-… [cited by applicant]
International Application No. PCT/CN2016/090642, International Search Report and Written Opinion mailed on Oct. 19, 2016, 5 pages. [cited by applicant]
Sun et al., Plasma DNA Tissue Mapping by Genome-Wide Methylation Sequencing for Noninvasive Prenatal, Cancer, and Transplantation Assessments, Proceedings of the National Academy of Sciences, vol. 112, No. 40, Sep. 21, … [cited by applicant]
Taiwan Application No. 105122965, Office Action mailed on May 29, 2020, 18 pages (8 pages of English Translation and 10 pages of Original Document). [cited by applicant]
Taiwan Application No. 110121521, Office Action mailed on Jul. 29, 2022, 8 pages (3 pages of English Translation and 5 pages of Original Document). [cited by applicant]
Zheng et al., Methylpurify: Tumor Purity Deconvolution and Differential Methylation Detection from Single Tumor DNA Methylomes, Genome Biology, Biomed Central Ltd, vol. 15, No. 8, Aug. 7, 2014, 13 pages. [cited by applicant]